Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 239

1.

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Saußele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R.

Leukemia. 2020 Apr;34(4):966-984. doi: 10.1038/s41375-020-0776-2. Epub 2020 Mar 3. Review.

PMID:
32127639
2.

Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements.

Tanasi I, Ba I, Sirvent N, Braun T, Cuccuini W, Ballerini P, Duployez N, Tanguy-Schmidt A, Tamburini J, Maury S, Doré E, Himberlin C, Duclos C, Chevallier P, Rousselot P, Bonifacio M, Cavé H, Baruchel A, Dombret H, Soulier J, Landman-Parker J, Boissel N, Clappier E.

Blood. 2019 Oct 17;134(16):1351-1355. doi: 10.1182/blood.2019001244. No abstract available.

PMID:
31434701
3.

Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients.

Nicolini FE, Dulucq S, Boureau L, Cony-Makhoul P, Charbonnier A, Escoffre-Barbe M, Rigal-Huguet F, Coiteux V, Varet B, Dubruille V, Lenain P, Rousselot P, Rea D, Guerci-Bresler A, Legros L, Liu J, Gardembas M, Ianotto JC, Turlure P, Johnson-Ansah H, Martiniuc J, Jardel H, Joly B, Zunic P, Henni T, Villemagne B, Berger MG, Cayssials E, Guilhot F, Larosa F, Guilhot J, Etienne G, Mahon FX.

Clin Cancer Res. 2019 Nov 15;25(22):6606-6613. doi: 10.1158/1078-0432.CCR-18-3373. Epub 2019 Jul 10.

PMID:
31292142
4.

Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome.

Berger MG, Pereira B, Rousselot P, Cony-Makhoul P, Gardembas M, Legros L, Escoffre-Barbe M, Nicolini FE, Saugues S, Lambert C, Réa D, Guerci-Bresler A, Giraudier S, Guilhot J, Saussele S, Mahon FX; (France Intergroupe des Leucémies Myéloïdes Chroniques).

Br J Haematol. 2019 Nov;187(3):337-346. doi: 10.1111/bjh.16083. Epub 2019 Jul 4.

PMID:
31271217
5.

Common clonal origin of an EBV-positive diffuse large B cell lymphoma and a chronic myelomonocytic leukemia.

Vasseur L, Lara D, Clappier E, Gillebert Q, Glaser C, Houlle-Crepin S, Ortonne N, Poullot E, Rousselot P, Besson C.

Leuk Lymphoma. 2019 Dec;60(13):3327-3329. doi: 10.1080/10428194.2019.1627539. Epub 2019 Jun 11. No abstract available.

PMID:
31184232
6.

Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review.

Cortes JE, Apperley JF, DeAngelo DJ, Deininger MW, Kota VK, Rousselot P, Gambacorti-Passerini C.

J Hematol Oncol. 2018 Dec 27;11(1):143. doi: 10.1186/s13045-018-0685-2. Review.

7.

Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study.

Heiblig M, Rea D, Chrétien ML, Charbonnier A, Rousselot P, Coiteux V, Escoffre-Barbe M, Dubruille V, Huguet F, Cayssials E, Hermet E, Guerci-Bresler A, Amé S, Sackmann-Sala L, Roy L, Sobh M, Morisset S, Etienne G, Nicolini FE.

Exp Hematol. 2018 Nov;67:41-48. doi: 10.1016/j.exphem.2018.08.006. Epub 2018 Sep 5.

PMID:
30195076
8.

Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia.

Hughes TP, Laneuville P, Rousselot P, Snyder DS, Rea D, Shah NP, Paar D, Abruzzese E, Hochhaus A, Lipton JH, Cortes JE.

Haematologica. 2019 Jan;104(1):93-101. doi: 10.3324/haematol.2018.188987. Epub 2018 Aug 9.

9.

Nivolumab to control molecular response in chronic myeloid leukemia.

Rousselot P, Renard P, de Buyer A, Finet A, Spentchian M, Saiag P.

Leuk Res. 2018 Sep;72:5-6. doi: 10.1016/j.leukres.2018.07.011. Epub 2018 Jul 26. No abstract available.

PMID:
30056299
10.

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.

Kreitman RJ, Dearden C, Zinzani PL, Delgado J, Karlin L, Robak T, Gladstone DE, le Coutre P, Dietrich S, Gotic M, Larratt L, Offner F, Schiller G, Swords R, Bacon L, Bocchia M, Bouabdallah K, Breems DA, Cortelezzi A, Dinner S, Doubek M, Gjertsen BT, Gobbi M, Hellmann A, Lepretre S, Maloisel F, Ravandi F, Rousselot P, Rummel M, Siddiqi T, Tadmor T, Troussard X, Yi CA, Saglio G, Roboz GJ, Balic K, Standifer N, He P, Marshall S, Wilson W, Pastan I, Yao NS, Giles F.

Leukemia. 2018 Aug;32(8):1768-1777. doi: 10.1038/s41375-018-0210-1. Epub 2018 Jul 20.

11.

The story of tyrosine kinase inhibitors discontinuation in clinical practice.

Rousselot P.

Leuk Lymphoma. 2018 Dec;59(12):2782-2791. doi: 10.1080/10428194.2018.1459611. Epub 2018 Jun 18.

PMID:
29909726
12.

Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial.

Huguet F, Chevret S, Leguay T, Thomas X, Boissel N, Escoffre-Barbe M, Chevallier P, Hunault M, Vey N, Bonmati C, Lepretre S, Marolleau JP, Pabst T, Rousselot P, Buzyn A, Cahn JY, Lhéritier V, Béné MC, Asnafi V, Delabesse E, Macintyre E, Chalandon Y, Ifrah N, Dombret H; Group of Research on Adult ALL (GRAALL).

J Clin Oncol. 2018 Aug 20;36(24):2514-2523. doi: 10.1200/JCO.2017.76.8192. Epub 2018 Jun 4.

13.

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

Cortes J, Perl AE, Döhner H, Kantarjian H, Martinelli G, Kovacsovics T, Rousselot P, Steffen B, Dombret H, Estey E, Strickland S, Altman JK, Baldus CD, Burnett A, Krämer A, Russell N, Shah NP, Smith CC, Wang ES, Ifrah N, Gammon G, Trone D, Lazzaretto D, Levis M.

Lancet Oncol. 2018 Jul;19(7):889-903. doi: 10.1016/S1470-2045(18)30240-7. Epub 2018 May 31.

PMID:
29859851
14.

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.

Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, Janssen JJWM, Mayer J, Koskenvesa P, Panayiotidis P, Olsson-Strömberg U, Martinez-Lopez J, Rousselot P, Vestergaard H, Ehrencrona H, Kairisto V, Machová Poláková K, Müller MC, Mustjoki S, Berger MG, Fabarius A, Hofmann WK, Hochhaus A, Pfirrmann M, Mahon FX; EURO-SKI investigators.

Lancet Oncol. 2018 Jun;19(6):747-757. doi: 10.1016/S1470-2045(18)30192-X. Epub 2018 May 4.

PMID:
29735299
15.

The rising prevalence of chronic myeloid leukemia in France.

Delord M, Foulon S, Cayuela JM, Rousselot P, Bonastre J.

Leuk Res. 2018 Jun;69:94-99. doi: 10.1016/j.leukres.2018.04.008. Epub 2018 Apr 17.

PMID:
29734071
16.

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.

Rea D, Ame S, Berger M, Cayuela JM, Charbonnier A, Coiteux V, Cony-Makhoul P, Dubruille V, Dulucq S, Etienne G, Legros L, Nicolini F, Roche-Lestienne C, Escoffre-Barbe M, Gardembas M, Guerci-Bresler A, Johnson-Ansah H, Rigal-Huguet F, Rousselot P, Mahon FX; French Chronic Myeloid Leukemia Study Group.

Cancer. 2018 Jul 15;124(14):2956-2963. doi: 10.1002/cncr.31411. Epub 2018 May 3.

17.

DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34+ CD15- cells in early chronic-phase chronic myeloid leukemia.

Maupetit-Mehouas S, Court F, Bourgne C, Guerci-Bresler A, Cony-Makhoul P, Johnson H, Etienne G, Rousselot P, Guyotat D, Janel A, Hermet E, Saugues S, Berger J, Arnaud P, Berger MG.

Mol Oncol. 2018 Jun;12(6):814-829. doi: 10.1002/1878-0261.12191. Epub 2018 Apr 27.

18.

Dasatinib dose management for the treatment of chronic myeloid leukemia.

Talpaz M, Saglio G, Atallah E, Rousselot P.

Cancer. 2018 Apr 15;124(8):1660-1672. doi: 10.1002/cncr.31232. Epub 2018 Jan 25. Review.

19.

Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia.

Ruggiu M, Oberkampf F, Ghez D, Cony-Makhoul P, Beckeriche F, Cano I, Taksin AL, Benbrahim O, Ghez S, Farhat H, Rigaudeau S, de Gunzburg N, Lara D, Terre C, Raggueneau V, Garcia I, Spentchian M, De Botton S, Rousselot P.

Leuk Lymphoma. 2018 Jul;59(7):1659-1665. doi: 10.1080/10428194.2017.1397666. Epub 2017 Nov 28.

PMID:
29179634
20.

Bosutinib-related pneumonitis.

Jutant EM, Meignin V, Montani D, Tazi A, Rousselot P, Bergeron A.

Eur Respir J. 2017 Sep 12;50(3). pii: 1700930. doi: 10.1183/13993003.00930-2017. Print 2017 Sep. No abstract available.

21.

Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs).

Aggoune D, Sorel N, Bonnet ML, Goujon JM, Tarte K, Hérault O, Domenech J, Réa D, Legros L, Johnson-Ansa H, Rousselot P, Cayssials E, Guerci-Bresler A, Bennaceur-Griscelli A, Chomel JC, Turhan AG.

Leuk Res. 2017 Sep;60:94-102. doi: 10.1016/j.leukres.2017.07.007. Epub 2017 Jul 26.

PMID:
28772207
22.

Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.

Legros L, Nicolini FE, Etienne G, Rousselot P, Rea D, Giraudier S, Guerci-Bresler A, Huguet F, Gardembas M, Escoffre M, Ianotto JC, Noël MP, Varet BR, Pagliardini T, Touitou I, Morisset S, Mahon FX; French Intergroup for Chronic Myeloid Leukemias.

Cancer. 2017 Nov 15;123(22):4403-4410. doi: 10.1002/cncr.30885. Epub 2017 Jul 25.

23.

The 67P/Churyumov-Gerasimenko observation campaign in support of the Rosetta mission.

Snodgrass C, A'Hearn MF, Aceituno F, Afanasiev V, Bagnulo S, Bauer J, Bergond G, Besse S, Biver N, Bodewits D, Boehnhardt H, Bonev BP, Borisov G, Carry B, Casanova V, Cochran A, Conn BC, Davidsson B, Davies JK, de León J, de Mooij E, de Val-Borro M, Delacruz M, DiSanti MA, Drew JE, Duffard R, Edberg NJT, Faggi S, Feaga L, Fitzsimmons A, Fujiwara H, Gibb EL, Gillon M, Green SF, Guijarro A, Guilbert-Lepoutre A, Gutiérrez PJ, Hadamcik E, Hainaut O, Haque S, Hedrosa R, Hines D, Hopp U, Hoyo F, Hutsemékers D, Hyland M, Ivanova O, Jehin E, Jones GH, Keane JV, Kelley MSP, Kiselev N, Kleyna J, Kluge M, Knight MM, Kokotanekova R, Koschny D, Kramer EA, López-Moreno JJ, Lacerda P, Lara LM, Lasue J, Lehto HJ, Levasseur-Regourd AC, Licandro J, Lin ZY, Lister T, Lowry SC, Mainzer A, Manfroid J, Marchant J, McKay AJ, McNeill A, Meech KJ, Micheli M, Mohammed I, Monguió M, Moreno F, Muñoz O, Mumma MJ, Nikolov P, Opitom C, Ortiz JL, Paganini L, Pajuelo M, Pozuelos FJ, Protopapa S, Pursimo T, Rajkumar B, Ramanjooloo Y, Ramos E, Ries C, Riffeser A, Rosenbush V, Rousselot P, Ryan EL, Santos-Sanz P, Schleicher DG, Schmidt M, Schulz R, Sen AK, Somero A, Sota A, Stinson A, Sunshine JM, Thompson A, Tozzi GP, Tubiana C, Villanueva GL, Wang X, Wooden DH, Yagi M, Yang B, Zaprudin B, Zegmott TJ.

Philos Trans A Math Phys Eng Sci. 2017 Jul 13;375(2097). pii: 20160249. doi: 10.1098/rsta.2016.0249.

24.

Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study.

Rea D, Henry G, Khaznadar Z, Etienne G, Guilhot F, Nicolini F, Guilhot J, Rousselot P, Huguet F, Legros L, Gardembas M, Dubruille V, Guerci-Bresler A, Charbonnier A, Maloisel F, Ianotto JC, Villemagne B, Mahon FX, Moins-Teisserenc H, Dulphy N, Toubert A.

Haematologica. 2017 Aug;102(8):1368-1377. doi: 10.3324/haematol.2017.165001. Epub 2017 May 18.

25.

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.

Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, Guerci-Bresler A, Legros L, Varet B, Gardembas M, Dubruille V, Tulliez M, Noel MP, Ianotto JC, Villemagne B, Carré M, Guilhot F, Rousselot P, Mahon FX.

J Clin Oncol. 2017 Jan 20;35(3):298-305. doi: 10.1200/JCO.2016.68.2914. Epub 2016 Oct 31.

PMID:
28095277
26.

Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy, for the prediction of subsequent cardiotoxicity.

Charbonnel C, Convers-Domart R, Rigaudeau S, Taksin AL, Baron N, Lambert J, Ghez S, Georges JL, Farhat H, Lambert J, Rousselot P, Livarek B.

Eur Heart J Cardiovasc Imaging. 2017 Apr 1;18(4):392-401. doi: 10.1093/ehjci/jew223.

PMID:
28064155
27.

Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study.

Rousselot P, Prost S, Guilhot J, Roy L, Etienne G, Legros L, Charbonnier A, Coiteux V, Cony-Makhoul P, Huguet F, Cayssials E, Cayuela JM, Relouzat F, Delord M, Bruzzoni-Giovanelli H, Morisset L, Mahon FX, Guilhot F, Leboulch P; French CML Group.

Cancer. 2017 May 15;123(10):1791-1799. doi: 10.1002/cncr.30490. Epub 2016 Dec 27.

28.

Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy for the prediction of subsequent cardiotoxicity.

Charbonnel C, Convers-Domart R, Rigaudeau S, Taksin AL, Baron N, Lambert J, Ghez S, Georges JL, Farhat H, Lambert J, Rousselot P, Livarek B.

Ann Cardiol Angeiol (Paris). 2016 Nov;65(5):380. doi: 10.1016/j.ancard.2016.09.033.

PMID:
27968773
29.

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.

Rea D, Nicolini FE, Tulliez M, Guilhot F, Guilhot J, Guerci-Bresler A, Gardembas M, Coiteux V, Guillerm G, Legros L, Etienne G, Pignon JM, Villemagne B, Escoffre-Barbe M, Ianotto JC, Charbonnier A, Johnson-Ansah H, Noel MP, Rousselot P, Mahon FX; France Intergroupe des Leucémies Myéloïdes Chroniques.

Blood. 2017 Feb 16;129(7):846-854. doi: 10.1182/blood-2016-09-742205. Epub 2016 Dec 8.

PMID:
27932374
30.

Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.

Guignabert C, Phan C, Seferian A, Huertas A, Tu L, Thuillet R, Sattler C, Le Hiress M, Tamura Y, Jutant EM, Chaumais MC, Bouchet S, Manéglier B, Molimard M, Rousselot P, Sitbon O, Simonneau G, Montani D, Humbert M.

J Clin Invest. 2016 Sep 1;126(9):3207-18. doi: 10.1172/JCI86249. Epub 2016 Aug 2.

31.

The Plasmair Decontamination System Is Protective Against Invasive Aspergillosis in Neutropenic Patients.

Fernandez-Gerlinger MP, Jannot AS, Rigaudeau S, Lambert J, Eloy O, Mignon F, Farhat H, Castaigne S, Merrer J, Rousselot P.

Infect Control Hosp Epidemiol. 2016 Jul;37(7):845-51. doi: 10.1017/ice.2016.81.

PMID:
27340735
32.

Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.

Shah NP, Rousselot P, Schiffer C, Rea D, Cortes JE, Milone J, Mohamed H, Healey D, Kantarjian H, Hochhaus A, Saglio G.

Am J Hematol. 2016 Sep;91(9):869-74. doi: 10.1002/ajh.24423. Epub 2016 Jun 20.

33.

Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation.

Chomel JC, Bonnet ML, Sorel N, Sloma I, Bennaceur-Griscelli A, Rea D, Legros L, Marfaing-Koka A, Bourhis JH, Ame S, Guerci-Bresler A, Rousselot P, Turhan AG.

Oncotarget. 2016 Jun 7;7(23):35293-301. doi: 10.18632/oncotarget.9182.

34.

Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL.

Rousselot P, Coudé MM, Gokbuget N, Gambacorti Passerini C, Hayette S, Cayuela JM, Huguet F, Leguay T, Chevallier P, Salanoubat C, Bonmati C, Alexis M, Hunault M, Glaisner S, Agape P, Berthou C, Jourdan E, Fernandes J, Sutton L, Banos A, Reman O, Lioure B, Thomas X, Ifrah N, Lafage-Pochitaloff M, Bornand A, Morisset L, Robin V, Pfeifer H, Delannoy A, Ribera J, Bassan R, Delord M, Hoelzer D, Dombret H, Ottmann OG; European Working Group on Adult ALL (EWALL) group.

Blood. 2016 Aug 11;128(6):774-82. doi: 10.1182/blood-2016-02-700153. Epub 2016 Apr 27.

35.

Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid Leukemia.

Vidal-Petiot E, Rea D, Serrano F, Stehlé T, Gardin C, Rousselot P, Peraldi MN, Flamant M.

Clin Lymphoma Myeloma Leuk. 2016 Mar;16(3):169-74. doi: 10.1016/j.clml.2015.12.001. Epub 2015 Dec 20.

PMID:
26795084
36.

[Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France Intergroupe des Leucémies Myéloïdes Chroniques].

Rea D, Ame S, Charbonnier A, Coiteux V, Cony-Makhoul P, Escoffre-Barbe M, Etienne G, Gardembas M, Guerci-Bresler A, Legros L, Nicolini F, Tulliez M, Hermet E, Huguet F, Johnson-Ansah H, Lapusan S, Quittet P, Rousselot P, Mahon FX, Messas E.

Bull Cancer. 2016 Feb;103(2):180-9. doi: 10.1016/j.bulcan.2015.11.008. Epub 2016 Jan 11. French.

PMID:
26790711
37.

Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study.

Nicolini FE, Etienne G, Dubruille V, Roy L, Huguet F, Legros L, Giraudier S, Coiteux V, Guerci-Bresler A, Lenain P, Cony-Makhoul P, Gardembas M, Hermet E, Rousselot P, Amé S, Gagnieu MC, Pivot C, Hayette S, Maguer-Satta V, Etienne M, Dulucq S, Rea D, Mahon FX.

Lancet Haematol. 2015 Jan;2(1):e37-46. doi: 10.1016/S2352-3026(14)00027-1. Epub 2015 Jan 7.

PMID:
26687426
38.

IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.

Debarri H, Lebon D, Roumier C, Cheok M, Marceau-Renaut A, Nibourel O, Geffroy S, Helevaut N, Rousselot P, Gruson B, Gardin C, Chretien ML, Sebda S, Figeac M, Berthon C, Quesnel B, Boissel N, Castaigne S, Dombret H, Renneville A, Preudhomme C.

Oncotarget. 2015 Dec 8;6(39):42345-53. doi: 10.18632/oncotarget.5645.

39.

Genetic polymorphisms associated with increased risk of developing chronic myelogenous leukemia.

Bruzzoni-Giovanelli H, González JR, Sigaux F, Villoutreix BO, Cayuela JM, Guilhot J, Preudhomme C, Guilhot F, Poyet JL, Rousselot P.

Oncotarget. 2015 Nov 3;6(34):36269-77. doi: 10.18632/oncotarget.5915.

40.

Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists.

Prost S, Relouzat F, Spentchian M, Ouzegdouh Y, Saliba J, Massonnet G, Beressi JP, Verhoeyen E, Raggueneau V, Maneglier B, Castaigne S, Chomienne C, Chrétien S, Rousselot P, Leboulch P.

Nature. 2015 Sep 17;525(7569):380-3. doi: 10.1038/nature15248. Epub 2015 Sep 2.

PMID:
26331539
41.

A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study.

Hunault-Berger M, Leguay T, Huguet F, Leprêtre S, Deconinck E, Ojeda-Uribe M, Bonmati C, Escoffre-Barbe M, Bories P, Himberlin C, Chevallier P, Rousselot P, Reman O, Boulland ML, Lissandre S, Turlure P, Bouscary D, Sanhes L, Legrand O, Lafage-Pochitaloff M, Béné MC, Liens D, Godfrin Y, Ifrah N, Dombret H; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL).

Am J Hematol. 2015 Sep;90(9):811-8. doi: 10.1002/ajh.24093.

42.

Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia.

Bibault JE, Figeac M, Hélevaut N, Rodriguez C, Quief S, Sebda S, Renneville A, Nibourel O, Rousselot P, Gruson B, Dombret H, Castaigne S, Preudhomme C.

Oncotarget. 2015 Sep 8;6(26):22812-21.

43.

Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia.

Chalandon Y, Thomas X, Hayette S, Cayuela JM, Abbal C, Huguet F, Raffoux E, Leguay T, Rousselot P, Lepretre S, Escoffre-Barbe M, Maury S, Berthon C, Tavernier E, Lambert JF, Lafage-Pochitaloff M, Lhéritier V, Chevret S, Ifrah N, Dombret H; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL).

Blood. 2015 Jun 11;125(24):3711-9. doi: 10.1182/blood-2015-02-627935. Epub 2015 Apr 15. Erratum in: Blood. 2015 Sep 3;126(10):1261.

PMID:
25878120
44.

Methane clathrates in the solar system.

Mousis O, Chassefière E, Holm NG, Bouquet A, Waite JH, Geppert WD, Picaud S, Aikawa Y, Ali-Dib M, Charlou JL, Rousselot P.

Astrobiology. 2015 Apr;15(4):308-26. doi: 10.1089/ast.2014.1189. Epub 2015 Mar 16. Review.

PMID:
25774974
45.

[What size of surgical margins for carcinoma of the eyelid?].

Mouriaux F, Stefan A, Coffin-Pichonnet S, Verneuil L, Rousselot P.

J Fr Ophtalmol. 2015 Feb;38(2):154-8. doi: 10.1016/j.jfo.2014.11.003. Epub 2015 Jan 27. Review. French.

PMID:
25637232
46.

Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia.

Rea D, Mirault T, Raffoux E, Boissel N, Andreoli AL, Rousselot P, Dombret H, Messas E.

Leukemia. 2015 May;29(5):1206-9. doi: 10.1038/leu.2014.342. Epub 2014 Dec 8. No abstract available.

PMID:
25482133
47.

Rapid clinical improvement of peripheral artery occlusive disease symptoms after nilotinib discontinuation despite persisting vascular occlusion.

Maurizot A, Beressi JP, Manéglier B, de la Marre NH, Spentchian M, Soury P, Solvet-Sebire P, Collet-Gaudillat C, Baud JM, Livarek B, Guilhot F, Rousselot P.

Blood Cancer J. 2014 Sep 19;4:e247. doi: 10.1038/bcj.2014.66. No abstract available.

48.

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.

Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Hernández-Boluda JC, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Baron R, Druker BJ, Deininger MW, O'Hare T.

Cancer Cell. 2014 Sep 8;26(3):428-442. doi: 10.1016/j.ccr.2014.07.006. Epub 2014 Aug 14.

49.

A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.

Seymour JF, Kim DW, Rubin E, Haregewoin A, Clark J, Watson P, Hughes T, Dufva I, Jimenez JL, Mahon FX, Rousselot P, Cortes J, Martinelli G, Papayannidis C, Nagler A, Giles FJ.

Blood Cancer J. 2014 Aug 15;4:e238. doi: 10.1038/bcj.2014.60.

50.

Reply to J. Richter et al.

Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, Gardembas M, Etienne G, Réa D, Roy L, Escoffre-Barbe M, Guerci-Bresler A, Tulliez M, Prost S, Spentchian M, Cayuela JM, Reiffers J, Chomel JC, Turhan A, Guilhot J, Guilhot F, Mahon FX.

J Clin Oncol. 2014 Sep 1;32(25):2823-5. doi: 10.1200/JCO.2014.56.3858. Epub 2014 Jul 28. No abstract available.

PMID:
25071119

Supplemental Content

Loading ...
Support Center